Therapeutic Advances in Medical Oncology最新文献

Background: Pembrolizumab plus chemotherapy (Pembrolizumab-CT) has been suggested as first-line treatment over pembrolizumab alone in aggressive non-small-cell lung cancer (NSCLC) with ⩾50% PDL1, but studies comparing these two strategies are lacking.

Objectives: To compare overall survival under pembrolizumab and Pembrolizumab-CT depending on tumor aggressiveness in PDL1 ⩾50% advanced NSCLC patients.

Design: A multicenter retrospective study was conducted of all patients with advanced NSCLC, PDL1 ⩾50% and ECOG 0-1, who received pembrolizumab or Pembrolizumab-CT as first-line treatment.

Methods: Tumor aggressiveness was defined as a sum of longest diameters (SLD) ⩾ 100 mm, a largest lesion diameter (LLD) >60 mm, ECOG 1, or need for corticosteroid therapy. Overall survival was analyzed in the whole population and in subgroups as restricted mean survival time (RMST) adjusted for the main prognostic variables.

Results: Ninety-six of the 164 included patients (58.5%) received pembrolizumab, and 68 (41.5%) received Pembrolizumab-CT. In the study group overall, the RMST was significantly shorter under Pembrolizumab-CT than under pembrolizumab (-7.9 months; p = 0.03). RMSTs were significantly shorter in the Pembrolizumab-CT group among patients with LLD <60 mm (-8.6 months, p = 0.04) and among ECOG-0 patients (-12.3 months, p < 0.001). RMSTs did not differ significantly between groups in patients with SLD ⩾ 100 mm (-1.1 months; p = 0.82), in patients with SLD <100 mm (-3.1 months, p = 0.54), in patients with LLD ⩾ 60 mm (0.9 months; p = 0.75), in patients with need for corticosteroid therapy (-2.9 months, p = 0.62), or in ECOG-1 patients (-6.1 months, p = 0.12). Toxicity-related hospitalizations appeared more frequent under Pembrolizumab-CT (20.5%) than under pembrolizumab (12.5%).

Conclusion: Pembrolizumab-CT was not associated with improved survival compared with pembrolizumab alone, in PDL1 ⩾ 50% advanced NSCLC patients, even in cases of aggressive disease. Chemotherapy-related toxicities may have had a negative effect on survival.

Background: Metastatic urothelial carcinoma (mUC) remains a challenging malignancy with limited treatment options. The combination of RC48 (Disitamab Vedotin) plus programmed cell death protein 1 (PD-1) inhibitor represents a promising therapeutic strategy.

Objectives: To evaluate the efficacy and safety of RC48 plus PD-1 inhibitors as first-line therapy for mUC in real-world practice.

Design: A multicenter, retrospective cohort study.

Methods: We retrospectively collected data from mUC patients who received RC48 plus PD-1 inhibitors as first-line therapy between July 2021 and February 2024 from three medical centers. Overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and disease control rate (DCR) were calculated to evaluate the clinical efficacy. Treatment-related adverse events (TRAEs) were analyzed to assess the safety profiles.

Results: A total of 63 patients with mUC were included, with a mean age of 67 years, and 71.4% were male. The most frequent metastatic sites were lymph nodes (77.8%), followed by the lung (31.7%), bone (23.8%), liver (19.0%), and others. The treatment response rates were as follows: 12 patients (19.0%) achieved a complete response, 33 patients (52.4%) had a partial response, and 10 patients (15.9%) experienced stable disease. The ORR was 71.4%, and the DCR was 87.3%. The median PFS was 10.5 months (95% confidence interval: 8.8-14.6 months), and the median OS was not reached. The most common TRAEs included fatigue (36.5%), anemia (34.9%), pruritus (33.3%), peripheral sensory neuropathy (28.6%), and nausea (28.6%). Grade III TRAEs occurred in seven patients (11.1%), and no Grade IV or V TRAEs were observed.

Conclusion: The combination of RC48 and PD-1 inhibitors administered in 3-week cycles demonstrates efficacy and manageable safety as first-line therapy for mUC patients in a real-world setting.

Background: Second-line options for biliary tract cancer (BTC) are limited. While nab-paclitaxel has demonstrated certain antitumor activity, evidence remains scarce. With gemcitabine-cisplatin plus anti-programmed death-ligand 1 (PD-(L)1) established as the first-line standard, the benefit of second-line immunotherapy-especially in patients without prior anti-PD-(L)1 exposure-remains unclear.

Objectives: To evaluate the efficacy and safety of nab-paclitaxel-based second-line treatments for advanced BTC, and compare outcomes between regimens with and without anti-PD-(L)1.

Design: This is a real-world retrospective study.

Methods: This study reviewed BTC patients who received second-line nab-paclitaxel-based therapy at West China Hospital between August 2018 and August 2023. The primary endpoint was overall survival (OS) in the entire population. Secondary endpoints were progression-free survival (PFS), response rate, adverse events (AEs) in the entire population, and comparison of survival outcomes and response rate between the chemo-anti-PD-(L)1 and chemotherapy groups.

Results: Among 84 patients (41 in the chemo-anti-PD-(L)1 group and 43 in the chemotherapy group), the median OS was 15.17 months (95% confidence interval (CI), 12.63-21.43), median PFS was 5.40 months (95% CI, 3.23-8.03), objective response rate (ORR) was 21.43% (95% CI, 13.22-31.74), and disease control rate (DCR) was 60.71% (95% CI, 49.45-71.20). Common grade 3-4 AEs were leukopenia (21.4%), neutropenia (17.9%), and anemia (13.1%). Hepatitis (14.6%) was the most frequent immune-related AE. Although a numerical trend favored the chemo-anti-PD-(L)1 group, no statistically significant differences were observed in OS (16.9 vs 14.6 months), PFS (7.3 vs 4.6 months), ORR (29.3% vs 13.9%), or DCR (68.3% vs 53.5%). In the entire cohort, radical surgery improved OS. In addition, patients with a baseline neutrophil-to-lymphocyte ratio ⩾3 and a ⩽30% reduction in carbohydrate antigen 19-9 from an initially elevated level during treatment had worse OS and PFS.

Conclusion: Nab-paclitaxel-based regimens represent a promising second-line treatment option for BTC. Although the improvement was not statistically significant, adding anti-PD-(L)1 therapy showed a trend toward improved survival.

Trial registration: ChiCTR2500096599.

Soft tissue sarcomas (STS) are rare mesenchymal tumors in which gene fusions occur in approximately one-third of cases, serving as key diagnostic and therapeutic targets. This study investigates the presence and implications of gene fusions in STS, focusing on a novel PRUNE2::NTRK2 gene fusion identified in two adult patients. The PRUNE2 gene plays a role in cellular processes and is a potential tumor biomarker. PRUNE2 plays a role in various tumors as a tumor suppressor, including prostate cancer, colorectal cancer, and neuroblastoma. The NTRK2 oncogene is, however, associated with tumor progression. In this report, we describe a possible molecular characterization of a novel PRUNE2::NTRK2 gene fusion. Although NTRK-associated fusions are significant in various cancers and have led to the development of targeted therapies, such as larotrectinib and entrectinib, the specific molecular impact of atypical PRUNE2::NTRK2 fusion remains unclear. The PRUNE2::NTRK2 gene fusions described here express a non-functional TrkB protein, and it is unclear whether the PRUNE2 function is intact or affected.

Background: The treatment response to radiotherapy of hepatocellular carcinoma (HCC) primary tumors and different types of tumor thrombus under identical radiation doses remains uncertain.

Objectives: This multicenter study aimed to evaluate and compare the radiotherapy responses of primary tumors (PT), portal vein tumor thrombus (PVTT), and hepatic vein tumor thrombus (HVTT) in HCC patients and to establish a prediction model for treatment response.

Design: This multicenter retrospective cohort study analyzed the treatment response of 242 HCC patients with macrovascular tumor thrombus who received radiotherapy combined with systemic therapy from five hospitals.

Methods: The objective response rate (ORR) was evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) V1.1 and modified RECIST (mRECIST) criteria. Independent factors of treatment response were identified by logistic regression analysis and used to create a nomogram. Model performance was evaluated through the area under the receiver operating characteristic curve (AUC), calibration curves, and decision curve analysis (DCA).

Results: Among the entire cohort, the ORRs evaluated by RECIST were 51.65% for PT, 56.32% for PVTT, and 81.93% for HVTT; the ORRs evaluated by mRECIST were 55.79% for PT, 62.63% for PVTT, and 87.95% for HVTT. Both criteria demonstrated that HVTT exhibited significantly higher response rates than PT and PVTT (p < 0.001). Multivariate logistic regression analysis identified irradiated primary tumor size, biologically effective dose, and tumor thrombus type as independent predictors of response in the radiation-field lesions. The developed nomogram showed good discriminative ability with an AUC of 0.788 in the training cohort and 0.736 in the external validation cohort. Calibration and DCA indicated that the model provided reliable predictions and substantial clinical benefit.

Conclusion: Under identical radiation doses, macrovascular tumor thrombus, especially HVTT, is associated with a higher response rate to radiotherapy compared to HCC primary tumors. The nomogram demonstrated good predictive performance, but prospective validation in larger cohorts is still warranted.

Background: Immune checkpoint inhibitors (ICIs) offer significant benefits for advanced non-small cell lung cancer (NSCLC) but yield objective response rates of only 10%-30% in unselected patients. Circular RNAs (circRNAs), implicated in cancer RNA dysregulation, may serve as biomarkers for ICI response.

Objectives: Identify circRNA signature to predict atezolizumab efficacy of NSCLC.

Design: This study analyzed circRNA expression profiles from 891 advanced NSCLC patients in the OAK and POPLAR clinical studies.

Methods: Based on The Cancer CircRNA Immunome Atlas database, we identified circRNAs associated with the efficacy of immunotherapy in NSCLC patients. Then, we establish predictive models for immunotherapy efficacy using multiple methods and conduct performance verification. Finally, we performed Gene Set Enrichment Analysis and Gene Set Variation Analysis to explore potential mechanisms.

Results: We identified an 11-circRNA signature, named circRNA-Sig, which predicted atezolizumab efficacy with an area under the curve of 0.71 in OAK and 0.67 in POPLAR. Survival analysis in OAK showed patients with low circRNA-Sig scores benefited more from ICI than chemotherapy (hazard ratio (HR) = 1.347; 95% confidence interval (CI): 1.049-1.730; p = 0.019), whereas those with high scores showed no significant difference (HR = 1.020; 95% CI: 0.796-1.307; p = 0.876). Enrichment analysis revealed that low-scoring patients exhibit an activated tumor immune microenvironment, with upregulated pathways in interferon-γ and IL-2/STAT5, which can activate immune cells such as CD8 + T cells and natural killer cells, suggesting mechanistic links to ICI sensitivity.

Conclusion: This circRNA-Sig model, validated across two large cohorts, offers a novel, clinically actionable tool for stratifying NSCLC patients for atezolizumab therapy, potentially enhancing personalized treatment strategies.

Uterine malignancies represent a broad and heterogeneous group of neoplasms, which collectively account for the majority of gynaecological malignancies in developed countries. For a significant proportion of these, mortality rates and clinical outcomes are of major concern, owing to complex molecular profiles and aggressive phenotypes that are largely refractory to conventional therapeutic approaches. Recent advancements in precision medicine and the development of targeted therapies have been transformative for several common cancer types; however, the same benefits are yet to be realised for many uterine cancers. This review comprehensively details the diverse molecular features characterising the various subtypes of uterine malignancies. Furthermore, we have examined the therapeutic approaches actively investigated to target these unique molecular features, identifying pathways and treatments that offer the greatest potential patient benefit. Among increasingly personalised strategies, particular promise is shown by HER2-targeted therapies for HER2-positive malignancies (e.g. trastuzumab deruxtecan). Additionally, targeting TP53 wild-type tumours with selinexor, as well as addressing AKT and DNA repair pathways in both uterine carcinomas and sarcomas (i.e. AKT inhibitor and poly(ADP-ribose) polymerase inhibitor combinations), represents key advancements. Furthermore, anti-angiogenic and immune checkpoint inhibitor combinations hold significant promise for future therapeutic strategies.

Background: Platinum-based chemotherapy has demonstrated superior efficacy as a first-line treatment for metastatic triple-negative breast cancer (mTNBC), at a cost of higher toxicity. Reliable prognostic tools are needed to refine risk stratification and facilitate individualized treatment discussions.

Objectives: To develop and validate prognostic nomograms for overall survival (OS) and progression-free survival (PFS) in patients with mTNBC receiving first-line platinum-based chemotherapy.

Design: Patient-level pooled analysis of prospective trial data, with internal and external validation.

Methods: Individual patient-level data of 777 mTNBC patients from 5 prospective clinical trials were collected. In total, 445 patients who received first-line platinum-based chemotherapy at our center were included as the PFP-TNBC cohort, which was randomly divided (7:3) into training and validation sets. An independent real-world cohort of 216 mTNBC patients was used for external validation. Multivariable Cox regression was used to construct OS and PFS models based on clinical characteristics, laboratory biomarkers, and regimen choice. Model performance was evaluated using concordance index (C-index), time-dependent area under the curve (AUC), calibration, and decision curve analysis.

Results: Both nomograms included the number of metastatic sites and the choice of platinum combination agent. The OS model additionally incorporated baseline cancer antigen 125 and lactate dehydrogenase; the PFS model included liver metastasis, baseline pain, and CA153 and carcinoembryonic antigen. For OS, the C-indexes were 0.67, 0.66, and 0.65 in the training, internal validation, and external cohorts, with AUCs of 0.71-0.74, 0.71-0.75, and 0.69-0.71 for 1-, 2-, and 3-year OS. For PFS, the C-indexes were 0.66, 0.62, and 0.61 in the training, internal validation, and external cohorts, with AUCs of 0.69-0.80, 0.66-0.74, and 0.63-0.72 for 6-, 12-, and 24-month PFS, respectively. Both models demonstrated good calibration and risk stratification identified groups with significantly different survival outcomes (log-rank p < 0.001).

Conclusion: The PFP-TNBC-OS and PFP-TNBC-PFS nomograms provide practical tools to estimate outcomes in mTNBC patients treated with first-line platinum chemotherapy. While C-index values indicated modest discrimination, time-dependent AUCs showed good accuracy at clinically relevant intervals. These models may aid risk stratification, patient counseling, and shared decision-making in chemotherapy-only settings. Future studies are warranted to evaluate their applicability in the evolving era of chemoimmunotherapy.

Background: Circulating tumor DNA (ctDNA) analysis that is tumor-informed and personalized requires high-quality tissue specimens, which are unavailable in certain clinical contexts and pathology practice in Southeast Asia.

Objectives: We aimed to develop and clinically validate an alternative tumor-naïve ctDNA assay.

Design: A retrospective observational study.

Methods: Our tumor-naïve multimodal profiling integrated mutation detection, using both amplicon and hybridization sequencing, with analysis of copy number alteration (CNA) and fragmentomics of cfDNA. We analyzed blood samples of 948 cancer patients and 566 non-cancer donors enrolled in previous studies to evaluate the analytical performance of ctDNA detection. Clinical performance was assessed using post-surgical samples of 97 breast cancer and 51 colorectal cancer patients to compare tumor-naïve ctDNA status with clinical recurrence. The performance was directly compared with the tumor-informed method using identical samples.

Results: For mutations, a combination of amplicon and hybridization sequencing provided higher sensitivity and broader coverage of mutation detection than single methods. Variants of clonal hematopoiesis of intermediate potential were common, mainly in the TP53 gene, and must be excluded. Besides mutations, the addition of CNA and fragment length profiles significantly improved the sensitivity of ctDNA detection in the metastatic stage, but modestly in the early stage. In breast cancer, surveillance tumor-naïve ctDNA achieved 54.5% sensitivity and 98.8% specificity for predicting recurrence (hazard ratio (HR) = 23.3, p < 0.0001). In colorectal cancer, the sensitivity and specificity of surveillance ctDNA for predicting recurrence were 80.0% and 100%, respectively (HR = 35.6, p < 0.0001). The overall accuracy of the tumor-naïve method was lower than the tumor-informed method, but the performance gap varied by cancer stage and cancer type.

Conclusion: The tumor-naïve method could be a reliable alternative to monitor ctDNA when obtaining high-quality tissue samples is challenging. The performance of this method was better in high ctDNA-shedding cancer or at the metastatic stage.

Background: Nanoliposomal irinotecan with fluorouracil and folinic acid (NFF) is a standard regimen for patients with unresectable or recurrent pancreatic cancer (urPC) after gemcitabine-based chemotherapy. However, little is known about the clinical impact of previous chemotherapy on the effects of NFF in the real world.

Objectives: We retrospectively evaluated whether the efficacy and safety of NFF differed depending on the history of prior chemotherapy among urPC patients receiving NFF.

Design: This study was conducted using the real-world data of Japanese patients with urPC who received NFF in the multicenter NAPOLEON-2 study.

Methods: We compared the efficacy and adverse events (AEs) after NFF initiation between previous irinotecan users and non-users, fluorouracil users and non-users, and platinum users and non-users. We also investigated whether the treatment duration of gemcitabine plus nab-paclitaxel (GnP) influenced the efficacy of NFF among patients treated with NFF as a second-line therapy after GnP.

Results: Overall, 161 patients were enrolled, all of whom had previously received gemcitabine. In the efficacy analysis between irinotecan users and non-users, the median overall survival (OS) was 9.2 and 8.0 months, respectively (hazard ratio (HR) 0.88; p = 0.66). For fluorouracil, the median OS was 9.1 months for users and 7.6 months for non-users (HR 0.98; p = 0.93). For platinum, the median OS was 9.1 months for users and 8.0 months for non-users (HR 0.88; p = 0.67). There was no clinical difference in AEs between irinotecan users and non-users, which affected ⩾10% of patients in both groups. The median OS in the group with previous GnP for ⩾7.8 months was 9.5 months, while it was 4.8 months in the group with GnP for <7.8 months (HR 0.50; p < 0.01).

Conclusion: NFF may be effective and tolerable, even in patients previously treated with irinotecan-, fluorouracil-, or platinum-based chemotherapy, in the real world.